- BioHarvest Sciences (BHSC) switches things up and hires Dr. Brian S. Cornblatt as Chief Medical Officer
- One goal in particular of BioHarvest is to set a path for the development of next-generation therapeutic solutions including botanical drugs
- Dr. Cornblatts story started back when he attended Johns Hopkins University, School of Medicine
- While obtaining his Ph.D. he also obtained a postdoctoral fellowship from the Johns Hopkins Bloomberg School of Public Health and more
- His most recent accomplishment/acheivement has been a novel line of products (and 18 related clinical trials)
- BioHarvest Sciences Inc. (BHSC) is down 1.72 per cent, trading at C$0.28 at close on May 31
BioHarvest Sciences Inc. (BHSC) has hired Dr. Brian S. Cornblatt as its Chief Medical Officer.
This new hire confirms how the company continues to strive in the direction to market scientific and clinically based therapeutic solutions from plants.
One goal in particular of BioHarvest is to set a path for developing next-generation therapeutic solutions, including botanical drugs.
Dr. Cornblatts story started back when he attended Johns Hopkins University School of Medicine, where he obtained his Ph.D. in Pharmacology and Molecular Sciences… Nothing complicated (joking, of course).
While obtaining his Ph.D., he also received a postdoctoral fellowship from the Johns Hopkins Bloomberg School of Public Health, Environmental Health Sciences Division of Toxicology.
During Dr. Cornblatt’s role as Director of Consumer Clinical Research and Science and as Medical Director at Nutramax Laboratories Consumer Care, he developed novel nutraceutical formulations and designed both in vitro and clinical studies to support products, and it didn’t end there.
His most recent accomplishment/achievement has been a novel line of products (and 18 related clinical trials) that deliver the essential ingredients needed to support sulforaphane production, a phytochemical with many emerging indications.
You could say Dr. Cornblatt is also an inventor of sorts, developing three issued patents and four pending provisional patents focused on plant-based bioactive compounds and health promotion.
“We are delighted to welcome Dr. Cornblatt to the leadership team at BioHarvest at a time of transition and growth for us,” said BioHarvest’s CEO, Ilan Sobel.
“As we […] move into medicinal prescription products with our polyphenol-based products and Cannabis product line up[, Dr. Cornblat will lead us,]” added Sobel.
Dr. Cornblatt added his thoughts on his new position, saying he’s “[…] excited about the opportunities that BioHarvest has in the medicinal space based on the CELLicitation™ technology.”
BioHarvest is seeking to receive authorization in Israel to produce Cannabis for commercial purposes and is also looking to expand production facilities to North America.
The company most recently mentioned how it has produced 10 kilograms of full-spectrum cannabis biomass on a commercial scale. This little production happened to be achieved without, get this, growing the plant itself.
BioHarvest has a market capitalization of roughly CAD$131M and has managed to raise over CAD$ 58M to date.
BioHarvest Sciences Inc. is a biotech firm focused on developing patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at an industrial scale, without the need to grow the plant itself.
BioHarvest Sciences Inc. (BHSC) is down 1.72 per cent, trading at C$0.28 at close on May 31.